Echo Health Ventures CEO Rob Coppedge was recently recognized by Global Corporate Venturing (GCV) on its list of CVC Titans, leaders who have been the head of their corporate venture capital unit for at least a decade. In profiling Coppedge, GCV took a long look at the history of Echo, which is celebrating its 10th anniversary this year.

Whereas many corporate venture units sputter out in a few years, Echo is going strong after a decade. Echo’s success was due to smart choices at its founding and then executing on those choices over the years, Coppedge told GCV.

(According to Coppedge) this was not a story of a clever fund simply out‑investing the market. It was the result of deliberate organisational design choices: opting to be a bridge rather than an island, creating a professional services arm that embeds resources inside the plans, actively engaging plan executives and their board members in Echo decision-making (including roles for the CEOs and CFOs on the investment committee), and intentionally developing a strong culture that values humility and clearly positioning Echo as a tool in service to the health plans, not a strategy in and of itself.

Echo was founded by Cambia Health Solutions and Blue Cross and Blue Shield of North Carolina, two independent health insurance companies on opposite ends of the country.

This was a unique idea in the market and especially among the Blues – and raised numerous structural and cultural questions. First off, the new combined unit needed to answer a foundational architectural question. To serve two companies, should it push for maximum independence, or go closer in?

“In the terms we use,” Coppedge recalls, “did we want to build a bridge or build an island”

An island model—spun out, more autonomous, closer to a traditional VC fund—would have insulated the team from corporate complexity. A bridge model would do the opposite: embed the venture platform more tightly into the daily life, governance and decision‑making of two different plans.

Echo chose the bridge.

Every major design decision followed from that choice. Instead of a lean IC of investors, the CEOs and CFOs of both plans joined the investment committee and meet monthly for deal review and approval. The board is stacked with those same executives plus independent directors from each plan. As Coppedge likes to tell other investors: “We built a governance model that involves a lot of people… it’s a feature, not a bug for us.

Echo has since added Arkansas Blue Cross and Blue Shield and BlueCross BlueShield of Tennessee and in recent years is measuring the healthcare impact of the partnerships between Echo portfolio companies and Echo health plan partners. See Echo’s 2025 Impact Report.

For decades, healthcare venture capital has justified itself by promising to reduce cost, improve quality, expand access and improve patient experience. Yet, (Coppedge) argues, “we have moved backwards on all those measures” in the US market since the mid‑1990s, despite billions invested and strong financial returns. By the standards applied to portfolio companies, the venture industry would not get a hall pass.

Echo is trying to address this by instrumenting the strategic side of its mandate. Together with its plan partners and external academics—including a collaboration with Duke University’s Margolis Institute for Health Policy —the firm is working to define frameworks and benchmarks for strategic value in healthcare CVC.

Echo and its partners are attempting to measure:

-Affordability
-Quality
-Engagement
-Competitiveness of the plans in their markets

These measures attempt to look at true impact to the market, the plan members, and the healthcare ecosystem. This is not simply an academic exercise. Echo’s argument is that if it holds itself accountable for impact on these dimensions, the composition of the partnership necessarily changes. Portfolio companies, health plans and Echo itself must all be at the table, not as vendor and buyer, but as co‑owners of outcomes. “It changes vendorship to partnership,” Coppedge says.

GCV concludes its profile by saying that Echo Health Ventures is a model for the corporate venture capital industry.

Echo Health Ventures is still a work in progress. Its impact measurement frameworks are evolving; its alliance may expand; its parent plans will continue to face their own market and regulatory upheavals. But as a 10‑year‑old healthcare CVC with multiple corporate parents, it has already exceeded the typical sector lifespan.

For CVC and corporate innovation leaders in other sectors, the Echo case offers a provocation: survival and impact are less about a clever thesis or a famous exit, and more about what you are willing to hard‑wire into your governance, operating model and culture.